AU2016335365B2 - Compounds and therapeutic uses thereof - Google Patents

Compounds and therapeutic uses thereof Download PDF

Info

Publication number
AU2016335365B2
AU2016335365B2 AU2016335365A AU2016335365A AU2016335365B2 AU 2016335365 B2 AU2016335365 B2 AU 2016335365B2 AU 2016335365 A AU2016335365 A AU 2016335365A AU 2016335365 A AU2016335365 A AU 2016335365A AU 2016335365 B2 AU2016335365 B2 AU 2016335365B2
Authority
AU
Australia
Prior art keywords
oxy
hydroxymethyl
nhac
pyran
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016335365A
Other languages
English (en)
Other versions
AU2016335365A1 (en
Inventor
Melanie Glossop
Christopher PICKFORD
Christine Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centauri Therapeutics Ltd
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of AU2016335365A1 publication Critical patent/AU2016335365A1/en
Application granted granted Critical
Publication of AU2016335365B2 publication Critical patent/AU2016335365B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)
  • Central Air Conditioning (AREA)
AU2016335365A 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof Active AU2016335365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1517859.3 2015-10-08
GBGB1517859.3A GB201517859D0 (en) 2015-10-08 2015-10-08 Novel compounds and therapeutic uses thereof
PCT/GB2016/053134 WO2017060729A1 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2016335365A1 AU2016335365A1 (en) 2018-04-26
AU2016335365B2 true AU2016335365B2 (en) 2021-12-09

Family

ID=55130801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016335365A Active AU2016335365B2 (en) 2015-10-08 2016-10-07 Compounds and therapeutic uses thereof

Country Status (10)

Country Link
US (2) US10953100B2 (enExample)
EP (1) EP3359201A1 (enExample)
JP (1) JP7065775B2 (enExample)
CN (1) CN108472381B (enExample)
AU (1) AU2016335365B2 (enExample)
CA (1) CA3001084A1 (enExample)
GB (1) GB201517859D0 (enExample)
IL (1) IL258511B (enExample)
WO (2) WO2017060728A1 (enExample)
ZA (1) ZA201802256B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014966B2 (en) 2016-09-13 2021-05-25 Centuari Therapeutics Limited Compounds and therapeutics uses thereof
GB201707076D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705684D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201707079D0 (en) * 2017-05-04 2017-06-21 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
CN111748089B (zh) * 2019-03-28 2023-07-18 成都先导药物开发股份有限公司 一种生物素标记化合物以及确定化合物结合靶标蛋白的方法
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
GB202406865D0 (en) 2024-05-15 2024-06-26 Centauri Therapeutics Ltd Novel compounds and therapeutics uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
AU2003255544A1 (en) * 2002-08-20 2004-03-11 Biotie Therapies Corp. Tumor specific oligosaccharide epitopes and use thereof
JP4430344B2 (ja) * 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
EP1653977A2 (en) * 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
CN101360728A (zh) * 2005-10-25 2009-02-04 艾吉拉医疗股份有限公司 Iap bir结构域结合化合物
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
JP2012526130A (ja) * 2009-05-05 2012-10-25 アルテルムネ テクフノロジエス，エルエルシー 化学的にプログラム可能な免疫
US9636419B2 (en) 2013-10-11 2017-05-02 The Universit of Kansas Targeting multiple receptors on a cell surface for specific cell targeting
GB201411150D0 (en) * 2014-06-23 2014-08-06 Altermune Technologies Llc Novel aptamers and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kristian S.A. et al, J Mol Med, 2015, 93, 619-631 *

Also Published As

Publication number Publication date
JP2018531287A (ja) 2018-10-25
JP7065775B2 (ja) 2022-05-12
AU2016335365A1 (en) 2018-04-26
CN108472381A (zh) 2018-08-31
US20210369850A1 (en) 2021-12-02
EP3359201A1 (en) 2018-08-15
WO2017060729A1 (en) 2017-04-13
US20180280521A1 (en) 2018-10-04
NZ741118A (en) 2024-07-26
IL258511B (en) 2021-10-31
ZA201802256B (en) 2019-01-30
IL258511A (en) 2018-06-28
CN108472381B (zh) 2023-06-06
US10953100B2 (en) 2021-03-23
WO2017060728A1 (en) 2017-04-13
CA3001084A1 (en) 2017-04-13
GB201517859D0 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
AU2016335365B2 (en) Compounds and therapeutic uses thereof
US12030892B2 (en) CRBN modulators
JP2018531287A6 (ja) 化合物及びそれらの治療用途
US20200270298A1 (en) Cyclic dinucleotides as anticancer agents
KR20230144550A (ko) 치료제로서의 cGAS 활성의 저해제
JP2022184922A (ja) 新規化合物及びその治療上の使用
US12162858B2 (en) Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R
US20230149551A1 (en) Arginine methyltransferase 5 (prmt5) degraders and uses thereof
WO2021252640A1 (en) Asparagine derivatives and methods of using same
EP3606558B1 (en) Novel compounds and therapeutic uses thereof
AU2018248706B2 (en) Novel compounds and therapeutic uses thereof
EP3947417A1 (en) Novel compounds and therapeutic uses thereof
WO2020074911A1 (en) Compounds and therapeutic uses thereof
US20220306630A1 (en) AGONISTS OF ROR GAMMAt
HK40011971B (en) Peptide compounds and therapeutic uses thereof
HK40011971A (en) Peptide compounds and therapeutic uses thereof
HK40023976B (en) Novel compounds and therapeutic uses thereof
HK40023976A (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)